Identification of the 5-HT1A serotonin receptor as a novel therapeutic target in a C. elegans model of Machado-Joseph disease

Identification of the 5-HT1A serotonin receptor as a novel therapeutic target in a C. elegans model of Machado-Joseph disease

Machado-Joseph disease (MJD) or Spinocerebellar ataxia type 3 (SCA3) is a progressive neurodegenerative disorder that affects movement coordination leading to a premature death. Despite several efforts, no disease-modifying treatment is yet available for this disease. Previous studies pinpointed the...

Full description

Bibliographic Details
Main Authors:	Joana Pereira-Sousa, Bruna Ferreira-Lomba, Aina Bellver-Sanchis, Daniela Vilasboas-Campos, Jorge H. Fernandes, Marta D. Costa, Mark A. Varney, Adrian Newman-Tancredi, Patrícia Maciel, Andreia Teixeira-Castro
Format:	Article
Language:	English
Published:	Elsevier 2021-05-01
Series:	Neurobiology of Disease
Subjects:	Befiradol NLX-112 5-HT1A receptor agonist Spinocerebellar ataxia type 3 Ataxin-3 aggregation Serotonin
Online Access:	http://www.sciencedirect.com/science/article/pii/S0969996121000279

Similar Items

Chemical Chaperones Reduce Aggregate Formation and Cell Death Caused by the Truncated Machado–Joseph Disease Gene Product with an Expanded Polyglutamine Stretch
by: Hideaki Yoshida, et al.
Published: (2002-07-01)

Twenty-five years since the identification of the first SCA gene: history, clinical features and perspectives for SCA1
by: Carlos Roberto Martins Junior, et al.

A Mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado–Joseph disease-like transgenic mice
by: Veronica F. Colomer Gould, et al.
Published: (2007-09-01)

Machado-Joseph Disease
by: J Gordon Millichap
Published: (1996-06-01)

Polyglutamine-expanded ataxin-3 activates mitochondrial apoptotic pathway by upregulating Bax and downregulating Bcl-xL
by: An-Hsun Chou, et al.
Published: (2006-02-01)

HDAC inhibitor sodium butyrate reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3
by: An-Hsun Chou, et al.
Published: (2011-02-01)

Polyglutamine-expanded ataxin-3 causes cerebellar dysfunction of SCA3 transgenic mice by inducing transcriptional dysregulation
by: An-Hsun Chou, et al.
Published: (2008-07-01)

Study of subcellular localization and proteolysis of ataxin-3
by: Chiara Pozzi, et al.
Published: (2008-05-01)

Pathogenesis of SCA3 and implications for other polyglutamine diseases
by: Hayley S. McLoughlin, et al.
Published: (2020-02-01)

Determining the Fate of Neurons in SCA3: ATX3, a Rising Decision Maker in Response to DNA Stresses and Beyond
by: Yingfeng Tu, et al.
Published: (2020-12-01)

The modulation of Amyotrophic Lateral Sclerosis risk by Ataxin-2 intermediate polyglutamine expansions is a specific effect
by: Suzana Gispert, et al.
Published: (2012-01-01)

State biomarkers for Machado Joseph disease: Validation, feasibility and responsiveness to change
by: Gabriel Vasata Furtado, et al.

RNAi or overexpression: Alternative therapies for Spinocerebellar Ataxia Type 1
by: Megan S. Keiser, et al.
Published: (2013-08-01)

Removal of the Polyglutamine Repeat of Ataxin-3 by Redirecting pre-mRNA Processing
by: Craig S. McIntosh, et al.
Published: (2019-10-01)

Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: Removal of the CAG containing exon
by: Melvin M. Evers, et al.
Published: (2013-10-01)

Broad Influence of Mutant Ataxin-3 on the Proteome of the Adult Brain, Young Neurons, and Axons Reveals Central Molecular Processes and Biomarkers in SCA3/MJD Using Knock-In Mouse Model
by: Kalina Wiatr, et al.
Published: (2021-06-01)

Trehalose alleviates the phenotype of Machado–Joseph disease mouse models
by: Magda M. Santana, et al.
Published: (2020-04-01)

Spinocerebellar Ataxia Type 2: Clinicogenetic Aspects, Mechanistic Insights, and Management Approaches
by: Luis C. Velázquez-Pérez, et al.
Published: (2017-09-01)

Polyglutamine-induced neurodegeneration in SCA3 is not mitigated by non-expanded ataxin-3: Conclusions from double-transgenic mouse models
by: Jeannette Hübener, et al.
Published: (2010-04-01)

Combined overexpression of ATXN1L and mutant ATXN1 knockdown by AAV rescue motor phenotypes and gene signatures in SCA1 mice
by: Carrell, E.M, et al.
Published: (2022)

Sleep disorders among Aboriginal Australians with Machado-Joseph Disease: Quantitative results from a multiple methods study to assess the experience of people living with the disease and their caregivers
by: Barker, R., et al.
Published: (2022)

Is the High Frequency of Machado-Joseph Disease in China Due to New Mutational Origins?
by: Tianjiao Li, et al.
Published: (2019-02-01)

Inhibition of colony-stimulating factor 1 receptor early in disease ameliorates motor deficits in SCA1 mice
by: Wenhui Qu, et al.
Published: (2017-05-01)

Altered Purkinje cell miRNA expression and SCA1 pathogenesis
by: Edgardo Rodriguez-Lebron, et al.
Published: (2013-06-01)

Neurodegenerative phosphoprotein signaling landscape in models of SCA3
by: Anna S. Sowa, et al.
Published: (2021-03-01)

Machado-Joseph Disease: from first descriptions to new perspectives
by: Bettencourt Conceição, et al.
Published: (2011-06-01)

Neural correlates of ataxia severity in spinocerebellar ataxia type 3/Machado-Joseph disease
by: Carlos R. Hernandez-Castillo, et al.
Published: (2017-06-01)

Mitochondrial Morphology, Function and Homeostasis Are Impaired by Expression of an N-terminal Calpain Cleavage Fragment of Ataxin-3
by: Tina Harmuth, et al.
Published: (2018-10-01)

Identifying Therapeutic Targets for Spinocerebellar Ataxia Type 3/Machado–Joseph Disease through Integration of Pathological Biomarkers and Therapeutic Strategies
by: Yu-Shuan Chen, et al.
Published: (2020-04-01)

Peripheral Oxidative Stress Biomarkers in Spinocerebellar Ataxia Type 3/Machado–Joseph Disease
by: Adriano M. de Assis, et al.
Published: (2017-09-01)

A família Drew de Walworth: um século após a avaliação inicial finalmente o diagnóstico doença de Machado-Joseph The Drew family of Walworth: one century from the first evaluation until the final diagnosis, Machado-Joseph disease
by: Hélio A. Ghizoni Teive, et al.
Published: (2004-03-01)

Otoneurological Abnormalities in Patients with Friedreich's Ataxia
by: Bianca Simone Zeigelboim, et al.
Published: (2017-01-01)

Atuação fonoaudiológica na doença de Machado-Joseph: relato de caso
by: Thames dos Santos Marques, et al.

Lithium carbonate and coenzyme Q10 reduce cell death in a cell model of Machado-Joseph disease
by: C.M. Lopes-Ramos, et al.

Neuronal cell culture from transgenic zebrafish models of neurodegenerative disease
by: Jamie R. Acosta, et al.
Published: (2018-10-01)

História natural da ataxia espinocerebelar tipo 3/Doença de Machado-Joseph com início na infância
by: Donis, Karina Carvalho
Published: (2015)

História natural da ataxia espinocerebelar tipo 3/Doença de Machado-Joseph com início na infância
by: Donis, Karina Carvalho
Published: (2015)

História natural da ataxia espinocerebelar tipo 3/Doença de Machado-Joseph com início na infância
by: Donis, Karina Carvalho
Published: (2015)

Motor uncoordination and neuropathology in a transgenic mouse model of Machado–Joseph disease lacking intranuclear inclusions and ataxin-3 cleavage products
by: Anabela Silva-Fernandes, et al.
Published: (2010-10-01)

GST-4-Dependent Suppression of Neurodegeneration in C. elegans Models of Parkinson’s and Machado-Joseph Disease by Rapeseed Pomace Extract Supplementation
by: Franziska Pohl, et al.
Published: (2019-10-01)